These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31634531)

  • 1. Pharmacokinetic and pharmacodynamic profiling of four antimicrobials against Acinetobacter baumannii infection.
    Zhu W; Chu Y; Zhang J; Xian W; Xu X; Liu H
    Microb Pathog; 2020 Jan; 138():103809. PubMed ID: 31634531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacodynamic simulation to evaluate tigecycline in treatment of nosocomial pneumonia caused by multidrug-resistant Acinetobacter baumannii.
    Ni WT; Liang BB; Cai Y; Liu YP; Bai N; Cui JC; Wang R
    Pak J Pharm Sci; 2014 May; 27(3):463-7. PubMed ID: 24811802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation.
    Eagye KJ; Kuti JL; Dowzicky M; Nicolau DP
    Clin Ther; 2007 May; 29(5):889-899. PubMed ID: 17697907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetics and Pharmacodynamics Modeling To Optimize Dosage Regimens of Sulbactam in Critically Ill Patients with Severe Sepsis Caused by Acinetobacter baumannii.
    Jaruratanasirikul S; Wongpoowarak W; Wattanavijitkul T; Sukarnjanaset W; Samaeng M; Nawakitrangsan M; Ingviya N
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7236-7244. PubMed ID: 27671056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics and Monte Carlo simulations of sulbactam to optimize dosage regimens in patients with ventilator-associated pneumonia caused by Acinetobacter baumannii.
    Jaruratanasirikul S; Nitchot W; Wongpoowarak W; Samaeng M; Nawakitrangsan M
    Eur J Pharm Sci; 2019 Aug; 136():104940. PubMed ID: 31132402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for the treatment of polymyxin B-resistant Acinetobacter baumannii infections.
    Menegucci TC; Albiero J; Migliorini LB; Alves JL; Viana GF; Mazucheli J; Carrara-Marroni FE; Cardoso CL; Tognim MC
    Int J Antimicrob Agents; 2016 May; 47(5):380-5. PubMed ID: 27068675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy and safety of colistimethate sodium in critical patients: an in vitro study by using of Monte Carlo simulation].
    Pan A; Mei Q; Yang T; Gao X; Lu H; Ye Y; Li J; Liu B
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2017 May; 29(5):385-389. PubMed ID: 28524024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetic-pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: dosing considerations for Acinetobacter baumannii infections.
    Yokoyama Y; Matsumoto K; Ikawa K; Watanabe E; Morikawa N; Takeda Y
    J Infect Chemother; 2015 Apr; 21(4):284-9. PubMed ID: 25638291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro synergistic activity of sulbactam in combination with imipenem, meropenem and cefoperazone against carbapenem-resistant Acinetobacter baumannii isolates].
    Turk Dagi H; Kus H; Arslan U; Tuncer I
    Mikrobiyol Bul; 2014 Apr; 48(2):311-5. PubMed ID: 24819268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacodynamic analysis of resistance trends in pathogens from patients with infection in intensive care units in the United States between 1993 and 2004.
    Eagye KJ; Nicolau DP; Lockhart SR; Quinn JP; Doern GV; Gallagher G; Abramson MA
    Ann Clin Microbiol Antimicrob; 2007 Oct; 6():11. PubMed ID: 17908321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant Acinetobacter baumannii.
    Ni W; Cui J; Liang B; Cai Y; Bai N; Cai X; Wang R
    J Antibiot (Tokyo); 2013 Dec; 66(12):705-8. PubMed ID: 23981963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro time-kill studies of antimicrobial agents against blood isolates of imipenem-resistant Acinetobacter baumannii, including colistin- or tigecycline-resistant isolates.
    Peck KR; Kim MJ; Choi JY; Kim HS; Kang CI; Cho YK; Park DW; Lee HJ; Lee MS; Ko KS
    J Med Microbiol; 2012 Mar; 61(Pt 3):353-360. PubMed ID: 22016557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
    Xiao YH; Hu YJ
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
    [No Abstract]   [Full Text] [Related]  

  • 14. Minocycline Alone and in Combination with Polymyxin B, Meropenem, and Sulbactam against Carbapenem-Susceptible and -Resistant Acinetobacter baumannii in an
    Beganovic M; Daffinee KE; Luther MK; LaPlante KL
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318006
    [No Abstract]   [Full Text] [Related]  

  • 15. Observation of clinical efficacy of the cefoperazone/sulbactam anti-infective regimen in the treatment of multidrug-resistant Acinetobacter baumannii lung infection.
    Wang Q; Huang M; Zhou S
    J Clin Pharm Ther; 2022 Jul; 47(7):1020-1027. PubMed ID: 35285526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Monte Carlo simulation to optimize antibiotic selection for bloodstream infections caused by Enterobacteriaceae in Shandong Province, China.
    Wang C; Bai Y; Li R; Shen C; Zhang J
    Diagn Microbiol Infect Dis; 2020 Jun; 97(2):115039. PubMed ID: 32253072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro evaluation of antimicrobial combinations against imipenem-resistant Acinetobacter baumannii of different MICs.
    Zhu W; Wang Y; Cao W; Cao S; Zhang J
    J Infect Public Health; 2018; 11(6):856-860. PubMed ID: 30057349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
    Karaoglan I; Zer Y; Bosnak VK; Mete AO; Namiduru M
    J Int Med Res; 2013 Dec; 41(6):1830-7. PubMed ID: 24265334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii.
    Housman ST; Hagihara M; Nicolau DP; Kuti JL
    J Antimicrob Chemother; 2013 Oct; 68(10):2296-304. PubMed ID: 23710070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Monte Carlo Simulation of Three Antimicrobials for Empiric Treatment of Adult Bloodstream Infections With Carbapenem-Resistant Enterobacterales in China.
    Zou D; Yao G; Shen C; Ji J; Ying C; Wang P; Liu Z; Wang J; Jin Y; Xiao Y
    Front Microbiol; 2021; 12():738812. PubMed ID: 34899628
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.